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Background: MicroRNAs have been demonstrated to play an important role in the pathogenesis of diabetic
nephropathy (DN). In this study, we investigated both the repertoire of miRNAs in the kidneys of patients with DN
and their potential regulatory role in inflammation-mediated glomerular endothelial injury.
Methods: The miRNA expression profiling of the renal biopsy samples was performed by a microarray analysis;
then, in situ hybridization and real-time polymerase chain reaction (PCR) were used to determine the localization
and expression of two of the miRNAs significantly up-regulated in human DN kidney samples, miR-155 and miR-
146a, in the kidney tissues from type 1 and type 2 DN rat models. Human renal glomerular endothelial cells
(HRGECs) cultured under high-glucose conditions were transfected with miR-155 and miR-146a mimics, and the
transforming growth factor (TGF)-β1, tumor necrosis factor (TNF)-α, and nuclear factor (NF)-κB expressions were
examined by western blot, real-time PCR, and an electrophoresis mobility shift assay.
Results: The expression of both miR-155 and miR-146a was increased more than fivefold in the kidney samples of
the DN patients compared with the controls, and the miR-155 expression was closely correlated with the serum
creatinine levels (R = 0.95, P = 0.004). During the induction and progression of the disease in type 1 and type 2 DN
rat models, miR-155 and miR-146a were demonstrated to increase gradually. In vitro, high glucose induced the
over-expression of miR-155 and miR-146a in the HRGECs, which, in turn, increased the TNF-α, TGF-β1, and
NF-κB expression.
Conclusions: Taken together, these findings indicate that the increased expression of miR-155 and miR-146a in the
DN patients and in the experimental DN animal models was found to contribute to inflammation-mediated
glomerular endothelial injury.Background
Complications affecting the macro- and microvasculature
are major causes of illness and death among diabetic pa-
tients. For example, diabetic nephropathy (DN), one of the
microvascular complications of diabetes mellitus, leads to
the development of end-stage renal disease [1]. In recent
years, our knowledge of DN pathophysiology has im-
proved on both genetic and molecular levels. Although
metabolic and hemodynamic alterations are traditionally* Correspondence: liufangfh@163.com
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and DN is considered to be a non-immune disease, accu-
mulating evidence now indicates that the immune system
is involved in the development and progression of its
pathophysiology [2]. DN is closely associated with the
chronic low-grade inflammation and activation of the in-
nate immune system [2-4]; and this is observed in patients
with diabetes in the elevated serum levels of antibodies
[5,6] and several inflammatory cytokines, primarily inter-
leukin (IL)-1, IL-6, and IL-18, as well as C-reactive protein
and tumor necrosis factor (TNF)-α [2,3,5].
MicroRNAs (miRNAs) are short non-coding RNAs that
modulate physiological and pathological processes by inhi-
biting target gene expression through the blockade ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Demographics of patients with DN
DN Control
n 6 3
Age (years) 51.7 ± 7.8 46.5 ± 6.7
Sex (male) 5 2
Smoking (%) 28.6 33.3
Duration of diabetes (years) 7.3 ± 5.3 0
Duration of DN (months) 12.1 ± 11.5 0
Diabetic retinopathy (n) 2 0
HbA1c (%) 7.5 ± 0.8 6.3 ± 0.4
Hemoglobin (g/L) 117.4 ± 30.1 132.5 ± 10.5
Serum albumin (g/L) 31.4 ± 9.9 46.5 ± 4.7
Serum creatinine(umol/L) 133.0 ± 60.8 77.4 ± 12.6
eGFR (ml/min) 62.2 ± 21.3 108.5 ± 14.8
TG (mmol/L) 1.7 ± 1.2 2.1 ± 0.7
CHOL (mmol/L) 5.4 ± 1.3 5.8 ± 1.1
HDL (mmol/L) 1.5 ± 0.4 1.4 ± 0.5
LDL (mmol/L) 3.2 ± 1.1 3.3 ± 1.3
Urinary protein excretion (g/24 h) 3.5 ± 2.0 0.062 ± 0.013
Mogensen stage of DN (n) [20]
Stage IV 5 0
Stage V 1 0
Pathologic classification of DN (n) [21]
Class 2 2 0
Class 3 2 0
Class 4 2 0
Data are n or means ± SD. The eGFR was calculated using the modification of
diet in renal disease formula.
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cent findings have revealed critical functions for specific
miRNAs in several cellular and biological processes, in-
cluding proliferation, differentiation, and development, as
well as in the regulation of genes relevant to cancer [6,7]
and the modulation of immune responses [8,9]. Although
several studies have evaluated the role of miRNAs in can-
cer, much less is known about their role in the field of dia-
betes and DN. Increasing evidence, predominantly from
animal models of diabetes, shows that several fibrosis-
related miRNAs, including miR-192 [10,11], miR-21 [12],
miR-377 [13], and miR-221 [14], are involved in hypergly-
cemic conditions in different intrinsic renal cell types. Spe-
cific miRNAs, such as miR-155 and miR-146a, were
initially linked with the inflammatory response by virtue
of their potent up-regulation in multiple immune cell line-
ages by Toll-like receptor ligands, inflammatory cytokines,
and specific antigens [15-17]. However, the pathogenic
role of these miRNAs in the development of DN remains
unknown.
Diabetic nephropathy primarily affects the glomerulus
[18]. Glomerular endothelial cells (GEC) are strategically
situated within the capillary loop adjacent to the glom-
erular mesangium and serve as targets of metabolic, in-
flammatory, biochemical, and hemodynamic signals that
regulate the glomerular microcirculation [19]. However,
the change in the GEC miRNA expression in response
to hyperglycemic stimuli and the role of miRNAs during
early and progressive DN are unclear.
In the present study, therefore, we aimed to clarify the
repertoire of miRNAs in the development and progression
of DN and the potential regulatory roles of miR-155 and
miR-146a in endothelial injury. Furthermore, we investi-
gated the mechanisms by which the nuclear factor (NF)-
κB signaling pathway mediates the high glucose-induced
expression of miR-155 and miR-146a in cultured human
renal glomerular endothelial cells (HRGECs).
Methods
Human kidney sample preparation
Six patients with type 2 DN were included in this study
(two women and four men, age 51.7 ± 7.8 years), and the
kidney tissues were obtained from renal biopsies. Renal
clinical staging and pathologic classification of these six
patients were referred to Mogosen stage of DN [20] and
pathologic classification of DN established by the Renal
Pathology Society [21]. Three patients who were diag-
nosed with renal carcinoma and were undergoing neph-
rectomy but were shown to be free from hypertension,
diabetes, and other co-morbidities were included as con-
trols (one woman and two men, age 44 ± 12.9 years,
urine test and serum creatinine were normal) (Table 1).
The OGTT of the three controls included in our study
was normal, thus, we thought they were not diabetes.Kidney tissues were obtained from renal biopsies (patients)
or nephrectomy surgery (controls, primarily kidney cor-
texes) after receiving signed informed consent from the in-
dividuals. Tissues were used for a miRNA microarray and
real-time polymerase chain reaction (PCR) or fixed in for-
malin and embedded in paraffin for histological and in situ
hybridization. Changes in the renal morphology were ex-
amined in formalin, paraffin-embedded tissue sections
(4 μm) stained with Periodic Acid-Schiff (PAS). The study
was approved by the Ethics Committee on Human Re-
search at Sichuan University (Sichuan, China).
MicroRNA microarray and data analysis
Dissected kidney tissue was homogenized, and RNA was
extracted using TRIzol (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s protocol. The RNA was
purified using a miRNeasy mini kit (QIAGEN) according
to the manufacturer’s instructions. The RNA’s quality
and quantity were determined using a Nanodrop 1000.
To study the miRNA-expression in the diabetic patients,
we performed a miRNA expression profiling of the
Huang et al. BMC Nephrology 2014, 15:142 Page 3 of 12
http://www.biomedcentral.com/1471-2369/15/142kidney samples from six diabetic patients and three
healthy controls using miRNA microarrays (Exiqon,
Vedbaek, Denmark) according to the manufacturer’s in-
structions; the miRNA microarray service was provided
by KangChen Bio-Tech, Inc., Shanghai, China. Briefly,
after the RNA isolation, the miRCURY™ Hy3™/Hy5™
Power labeling kit (Exiqon, Vedbaek, Denmark) was
used according to the manufacturer’s guidelines for
miRNA labeling. One microgram of each sample was 3’-
end-labeled with a Hy3TM fluorescent label by combin-
ing the RNA (one microgram) in 2.0 μL of water with
1.0 μL of CIP buffer (0.5 μL) and CIP (0.5 μL) (Exiqon).
The mixture was incubated for 30 min at 37°C, and the
reaction was terminated by incubation for 5 min at
95°C. Then, 3.0 μL of the labeling buffer, 1.5 μL of the
fluorescent label (Hy3TM), 2.0 μL of the DMSO, and
2.0 μL of the labeling enzyme (this enzyme was actually a
labeling enzyme from the miRCURYTM Array Power La-
beling kit (Cat #208032-A, Exiqon)) were added to the mix-
ture. The labeling reaction was incubated for 1 h at 16°C,
and the reaction was stopped by incubation for 15 min at
65°C. The Hy3TM-labeled sample (25 μL) with 25 μL of
hybridization buffer was denatured for 2 min at 95°C, incu-
bated on ice for 2 min, and then hybridized to the miR-
CURYTM LNA Array (v.16.0) (Exiqon), according to the
manufacturer’s instructions, for 16–20 h at 56°C in a 12-
Bay hybridization system (Hybridization System; Nimblegen
Systems, Inc., Madison, WI, USA). Following hybridization,
the slides were washed several times using a wash buffer
kit (Exiqon) and dried by centrifugation for 5 min at
400 rpm (the slides were dried by centrifugation for 5 min.
at 1000 rpm). The slides were then scanned using the
Axon GenePix 4000B microarray scanner (Axon Instru-
ments, Foster City, CA, USA), and the images were
imported using GenePix Pro 6.0 software (Axon Instru-
ments) for the grid alignment and data extraction. The
replicated miRNAs were averaged, and those with inten-
sities ≥50 were selected to calculate the normalization
factor. After normalization, the significant differentially
expressed miRNAs were identified through Volcano Plot
filtering. Hierarchical clustering was performed using
MEV software (v4.6, TIGR) (Figure 1).
In situ hybridization
Locked nucleic acid-based in situ detection of miRNA in
kidney sections was performed. Briefly, the kidney samples
were fixed at 4°C in formalin, embedded in paraffin wax,
and cut into 4 μm sections. Dig-labeled probes were de-
signed and synthesized by Invitrogen Inc. The sequences
of the Dig-labeled probes against miR-155 and miR-146a
mRNA were as follows: miR-155: 5′-CCCCTATCACG
ATTAGCATTAA-3′, miR-146a: 5′-AACCCATGGAATTC
AGTTCTCA-3′. A scrambled probe sequence: 5′-TTCAC
AATGCGTTATCGGATGT-3′ was used as negativecontrol for non-specific hybridization signal. In situ
hybridization was performed using a detection kit on the
sections of 4% paraformaldehyde-fixed (containing 0.1%
diethylpyrocarbonate) kidney tissues according to the
manufacturer’s instructions.
Rat models
Littermate Sprague Dawley (SD) rats (male, aged 6 weeks,
200–220 g) were kept under laboratory standard condi-
tions at a temperature of 22 ± 2°C, with a 12-h light/
12-h dark cycle and relative humidity of 40%–60%. They
were divided into two groups: the non-diabetic rats
(controls, n = 6) and the streptozotocin (STZ)-induced
type 1 diabetes rats (DM, n = 18). The DM rat models
were induced by an intraperitoneal injection of a single
dose of 60 mg/kg STZ (Sigma, St. Louis, MO, USA) in
citrate buffer (pH 4.5). The random blood glucose level
was tested using a glucometer (Accu-Chek, Roche, Basel,
Switzerland), and blood glucose levels were determined
on days 3 and 7 after the STZ injection. Only the rats
with glucose concentrations ≥16.7 mmol/L for 3 con-
secutive days were used in the study. The DM rats were
euthanized in weeks 1, 4, and 8 after the induction of
diabetes, and their kidneys were harvested. Their renal
cortexes were collected for real-time PCR by carefully
removing the renal pelvis and medullar tissues. The ex-
perimental protocol was approved by the Animal Experi-
mentation Ethics Committee at Sichuan University.
In a separate experiment to generate type 2 diabetes SD
rats, rats (male, aged 6 weeks, 200–220 g) were allocated to
one of two dietary regimens for an initial period of 6 weeks:
a normal pellet diet (NPD, n = 6) or a high-fat and high-
sugar diet (HFD, containing a regular diet plus 27.3% lard,
54.6% sucrose, 16.4% cholesterol, and 1.6% sodium cholate
(w/w), n = 18). After this time, the HFD animals with high
HOMA-IR (fasting plasma glucose (mmol/L) × fasting insu-
lin (mIU/L) ÷ 22.5) were defined as insulin resistant and
were injected with multiple low-doses of STZ (four doses
of 25 mg/kg; Sigma, St. Louis, MO, USA) in citrate buffer
(pH 4.5) after overnight fasting. The NPD animals were
injected with a citrate buffer (1 mL/kg). The rats with fast-
ing glucose levels ≥16.7 mmol/L 72 h after the STZ injec-
tion for 3 consecutive days were used for the study. The
rats were kept on their respective diets until the end of the
study. The DM rats were euthanized in weeks 0, 8, and 16
after the induction of diabetes, and their kidneys were har-
vested and their renal cortexes collected as before. All of
the experimental protocols involving the animals were ap-
proved by the Animal Experimentation Ethics Committee
at Sichuan University.
Biochemical measurements in rat diabetes
Fasting (6 h) blood glucose levels were determined weekly
for the first 2 weeks then every 2 weeks thereafter by using
Figure 1 Hierarchical clustering for the differentially expressed miRNAs in DN vs the controls. The heat-map was generated by the unsupervised
hierarchical clustering of the miRNA profiles of 6 diabetic patients and 3 healthy controls. The threshold we used to screen up- or down-regulated miRNAs
was fold change≥ 2.0. Heat map legend: Red = up-regulation, green = down-regulation. The gene and column rows represent the sample.
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Australia). Before the disease induction (week 0), urine
was collected for 24 h by placing rats in metabolic cages
and performing a urinary albumin excretion assay. This
process was repeated after the disease induction (for
type 1 diabetes: weeks 1, 4, and 8; for type 2 diabetes:
weeks 0, 8, and 16). The urinary albumin was measured
by a competitive ELISA according to the manufacturer’s
instructions (MaxiSorp Surface Immuno Plates™; Nunc,
Roskilde, Denmark). The serum creatinine was detected
by the QuantiChrom Creatinine Assay Kit (BioAssay
Systems, Hayward, CA, USA).Quantitative real-time PCR for miR-155 and miR146a
expression in the human and the rat kidneys
To confirm the miRNA profiling findings in the human
subjects, we used a quantitative real-time PCR to measure
the expression of miR-155 and miR-146a in both the hu-
man and the rat kidneys. The reverse transcription reaction
used MMLV reverse transcriptase (Epicenter, Madison, WI,
USA), and a quantitative PCR was performed using an ABI
PRISM7500 system (Applied Biosystems, Foster City, CA,
USA). miR-155 and miR-146a were further quantified with
a TaqMan quantitative real-time PCR. The PCR primers
used are shown in Table 2.
Table 2 The primer sequence of real-time PCR
Gene Primer sequences
hsa-miR-155 RT 5′-GCGCGTGAGCAGGCTGGAGAAATTAACCACGCGCACCCCT-3′
Forward 5′- CTTAATGCTAATCGTGAT -3′
Reverse 5′- GAG CAG GCT GGA GAA -3′
hsa-miR-146a RT 5′-GCGCGTGAGCAGGCTGGAGAAATTAACCACGCGCAACCCA -3′
Forward 5′- CTGAGAACTGAATTCCA -3′
Reverse 5′- GAG CAG GCT GGA GAA -3′
U6 RT 5′-CGCTTCACGAATTTGCGTGTCAT -3′
Forward 5′- CTCGCTTCGGCAGCACATA -3′
Reverse 5′- CGCTTCACGAATTTGCGTG -3′
TGF-β1 Forward 5′- CCAACTATTGCTTCAGCTCCA -3′
Reverse 5′- GTGTCCAGGCTCCAAATGT -3′
TNF-α Forward 5′- CCCAGGGACCTCTCTCTAATCA -3′
Reverse 5′- AGCTGCCCCTCAGCTTGAG -3′
GAPDH Forward 5′-CCCCTTCATTGACCTCAACTAC-3′
Reverse 5′-GATGACAAGCTTCCCGTTCTC-3′
Huang et al. BMC Nephrology 2014, 15:142 Page 5 of 12
http://www.biomedcentral.com/1471-2369/15/142Cell culture
Normal HRGECs were purchased from ScienCell Re-
search Laboratories (Carlsbad, CA, USA) and cultured
in an endothelial cell medium (ScienCell) containing 5%
fetal bovine serum and 1% endothelial cell growth sup-
plement at 37°C in a 5% CO2 atmosphere. The cells were
serially passaged by a brief exposure to 0.25% trypsin
(BD-Difco, USA) and 0.04% EDTA (Sigma, St. Louis,
MO, USA), and the experiments were performed in the
cells at passages 2–5 at 80% confluence. They were
seeded at a density of 1 × 105 cells/well in 6-well dishes
or 2.5 × 105 cells/25 cm2 flask. Prior to the experiments,
the cells were fasted for 24 h in maintenance media.
To detect the time-dependent changes in the miR-155
and miR-146a expression, the cells cultured with me-
diums containing 25 mmol/L glucose were cultured at
37°C in 5% CO2 for 0, 0.5, 1, 2, 4, 8, and 24 h. They were
then collected for a real-time PCR. Chemically modified
RNA oligonucleotides comprising a sequence comple-
mentary to mature miR-155 and miR-146a (miR-155
and miR-146a inhibitors) were used to inhibit the miR-
155 and miR-146a activities. The miR-155 and miR-146a
mimics were double-stranded constructs consisting of a
guide and passenger strands. An oligonucleotide con-
taining a four-base mismatch (nontargeting scramble
RNA) was used as a negative control. Pyrrolidine dithio-
carbamate (PDTC, Sigma) was used as an NF-κB inhibi-
tor. According to the set time points, the HRGECs (1 ×
105 per well) were transfected with miR-155 and miR-
146a mimics, inhibitors, and scramble control after 24 h
of starvation in a serum-free medium using Lipofecta-
mine 2000 (Invitrogen) according to the manufacturer’s
instructions.Western blot analysis
The proteins were extracted from the HRGECs using a
RIPA lysis buffer and analyzed by western blot as described
previously [17]. Briefly, after blocking the nonspecific bind-
ing with 5% bovine serum albumin, the membranes were
incubated with primary antibodies against TNF-α and
transforming growth factor (TGF)-β1 overnight at 4°C.
After washing, the membranes were incubated with IRDye
800-conjugated secondary antibodies (Rockland Immuno-
chemicals, Inc., Gilbertsville, PA, USA), and the signals
were detected using the Odyssey Infrared Imaging System
(Li-COR Biosciences, Lincoln, NE, USA) and quantitated
with Image J software (NIH). The protein ratio was normal-
ized against the GAPDH and expressed as the mean ±
standard errors of the mean (SEM).
Quantitative real-time PCR for mRNA expression in HRGECs
The total RNA was extracted from the HRGECs using the
RNeasy kit according to the manufacturer’s instructions
(Qiagen Inc., Valencia, CA, USA), and the cDNA was syn-
thesized. A real-time PCR was performed with the Opti-
con®2 Real-Time PCR detector (Bio-Rad, Hercules, CA,
USA) using the IQ SYBR green supermix reagent (Bio-
Rad) as described previously [17]. The primers used to
amplify the mRNAs of TNF-α, TGF-β1, and GAPDH are
listed in Table 2. The housekeeping gene GAPDH was
used as an internal standard. The ratios of specific mRNA:
GAPDH mRNA were calculated and expressed as the
mean ± SEM.
EMSA of NF-κB in HRGECs
EMSA was performed using the LightShift™ chemilumin-
escent EMSA kit (Pierce Biotechnology, Rockford,
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Nuclear proteins were extracted from the HRGECs using
a nuclear extraction kit (Pierce Biotechnology, Rockford,
Illinois, USA) and incubated with a biotin-labeled NF-κB
probe (5′-AGT TGA GGG GAC TTT CCC AGG C-3′)
at room temperature for 20 min. Samples were separated
by 6% non-denaturing polyacrylamide gel electrophoresis
and transferred to a positively charged nylon membrane
(0.45 μm, Pierce Biotechnology, Rockford, Illinois, USA).
Statistical analyses
The data obtained were expressed as the mean ± SEM.
The statistical analyses were performed using a linear
correlation analysis and one-way analysis of variance
followed by a two-tailed Newman-Keuls post-test (Prism
3.0 GraphPad Software, Inc., San Diego, CA, USA). P-
values <0.05 were considered statistically significant.
Results
Characteristics of the research participants
The clinical and pathological characteristics of the pa-
tients are shown in Table 1. The cases of DN were not-
able for their statistically significant decreased estimated
glomerular filtration rate (eGFR), increased proteinuria,
serum creatinine levels, and increased glycosylated
hemoglobin compared with the controls. They were also
defined by the presence of diabetes, proteinuria, histo-
logical changes, and the absence of hepatitis, HIV, lupus,
or other potential causes of glomerulonephritis. Three
control samples were obtained from the healthy or biop-
sied samples of the unaffected portions of the tumor
nephrectomies. The control subjects were defined as
having normal serum creatinine levels and eGFR and an
absence of proteinuria and hematuria.
Aberrant expression of miR-155 and miR-146a between
healthy and type 2 diabetic human kidney tissues
The miRNA expression of the kidney tissues was ana-
lyzed using microarray screening. Compared with the nor-
mal controls, the 71 miRNAs in the type 2 DN patient
samples were differentially expressed, with 32 elevated and
39 down-regulated (Figure 1). Thirty-one miRNAs were
upregulated by ≥ 2-fold in the DN kidney samples from
the DN patients, in which there were two significantly
upregulated miRNAs, miR-155 (6.22 ± 2.81-fold) and miR-
146a (4.87 ± 1.39-fold). These findings were further con-
firmed by a quantitative real-time PCR for miR-155 and
miR-146a (Figure 2A,B).
The morphology of the kidney glomeruli from the DN
patients was examined using PAS staining. The precise lo-
cation and expression levels of the miR-155 and miR-146a
were determined using in situ hybridization in the patient
and control kidney tissue sections stained with Dig-labeled
miR-155 and miR-146a riboprobes. The miR-155 and miR-146a were primarily localized in the GECs, mesangial areas
and tubular sections of the DN kidneys, and the staining
was significantly stronger in the DN GECs compared
with the control samples (Figure 2C,D), which is consistent
with the quantitative real-time PCR results above. To under-
stand how these differentially expressed miRNAs might
contribute to the inflammatory response, we searched for
their potential regulatory targets using algorithms based
on miRNA-mRNA complementarity and evolutionary
conservation seed sequences (Target-Scan and PicTar).
Surprisingly, some of the candidate targets of miR-155
and miR-146a were involved in the inflammatory re-
sponses (data not shown); therefore, we used miR-155 and
miR-146a as targets for further study.
Correlation between miRNA expression, serum creatinine
levels, and urinary protein excretion
The linear correlation analysis revealed that the miR-155
expression was closely correlated with the serum cre-
atinine levels (R = 0.95, P = 0.004) but not with the urin-
ary protein excretion levels (R = 0.336, P = 0.461); there
were also no significant correlations between the miR-
146a and serum creatinine levels (R = 0.531, P = 0.220)
or the urinary protein excretion levels (R = 0.360, P =
0.427) (Figure 3).
Altered miR-155 and miR-146a expression in type 1 and
type 2 DN rat kidneys
In the rats with type 1 DN, the rats were sacrificed after the
induction of diabetes at 1, 4, and 8 weeks (serum creatinine
and urinary protein excretion were shown in Table 3), and
a quantitative real-time PCR was used to show that the ex-
pression of miR-155 and miR-146a gradually increased dur-
ing the progression of the DN (Figure 4A,B). A similar
trend was observed for miR-155 and miR-146a expression
in the development and progression of DN in the rats with
type 2 DN (Figure 5A,B). In comparison with the NPD
control group, the expression levels of miR-146a and miR-
155 were significantly increased in the type 2 DN rats from
week 0 to week 8 and 16 (Figure 5A,B) (serum creatinine
and urinary protein excretion were shown in Table 4).The role of the NFκB signaling pathway in miR-155 and
miR-146a-mediated renal inflammation and fibrosis
To determine the effects of high glucose on the expres-
sion of miR-155 and miR-146a, the HRGECs stimulated
with a medium containing 25 mmol/L glucose were cul-
tured at 37°C in 5% CO2 for 0, 0.5, 1, 2, 4, 8, and 24 h.
The expression of both the miR-155 and miR-146a was
up-regulated 2 h after the glucose stimulation, peaked
after 4 h, and then decreased until 24 h (with a minor
increase of the miR-155 expression) relative to the con-
trol and the mannitol groups (Figure 6A,B).
Figure 2 The expressions and distribution of miR-155 and miR-146a in the kidneys from DN patients. miR-155 and miR-146a were primarily
localized in the glomerular endothelial cells, the mesangial areas and the tubular sections in kidneys from DN. A, B: miR-155 and miR-146a expressions
in the kidney of the DN and controls were confirmed by quantitative real-time PCR. C, D: In situ hybridization was performed to determine the
distribution of miR-155 and miR-146a in the kidneys from the DN patients. *p < 0.05.
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on the HRGECs under high-glucose conditions, the
HRGECs were categorized as the normal control (contain-
ing 5 mmol/L glucose), mannitol (20 mmol/L mannitol),
high glucose (containing 25 mmol/L glucose), high glucose
+miR-155 mimic (50 nmol/L), high glucose +miR-155 in-
hibitor (100 nmol/L), high glucose + Scrambled miRNA
(50 nmol/L), high glucose + PDTC (100 μmol/L), and high
glucose +miR155 (50 nmol/L) + PDTC (100 μmol/L)
groups. These cells were transfected with miR mimics or
inhibitors as indicated, then harvested 24 h after transfec-
tion for the real-time PCR analysis and after 48 h for the
western blot analysis. Compared with the normal control
and mannitol groups, high glucose levels induced the up-
regulation of both proinflammatory cytokines (TNF-α) and
pro-fibrotic growth factors (TGF-β1), as shown by both
the real-time PCR (Figure 6C,D) and western blotting
(Figure 6E,F). Under high-glucose conditions, the HRGECs
overexpression of miR-155 or miR-146a following the
transfection with miR-155 or miR-146a mimics showed an
additive effect on the TNF-α and TGF-β1 upregulation.
However, the induction by glucose was clearly blunted by
the miR-155 and miR-146a inhibitors, suggesting that miR-
155 and miR-146a could significantly induce renal inflam-
mation and fibrosis and contribute to HRGEC injury.
To clarify the underlying NF-κB signaling pathway, the
DNA-binding activity of NF-κB was assessed by EMSAusing nuclear extracts from the HRGECs. A strong nu-
clear activation of NF-κB was observed in the cells from
the miR-155 and miR-146a group (Figure 6G,H). Fur-
thermore, the addition of PDTC partially repressed the
up-regulated expression of TNF-α and TGF-β1 caused
by the activation of NF-κB in the miR-155 and miR-146a
over-expressing groups.
Discussion
Recent evidence suggests that miRNAs can serve as im-
portant therapeutic targets in a wide range of human dis-
eases [22] in which they can regulate the expression of key
genes [23]. As such, some miRNAs have been suggested
to have the potential to be novel diagnostic and thera-
peutic targets for diabetic complications [24]. Reports have
shown that several miRNAs (miR-192, −194, −204, −215,
and −216) are highly and quite exclusively expressed in
the kidney [25], of which miR-192 was found to target
SIP1, a major effector of the TGF-β signaling pathway
[10]. Moreover, miR-377 is up-regulated in human and
mouse mesangial cells exposed to high-glucose levels and
can lead to increased fibronectin production in DN [13],
while miR-216a regulates the collagen type I alpha 2 gene
through mechanisms involving inhibition of the RNA
binding protein Ybx1 [26]. Under hyperglycemic condi-
tions, miR-221 is induced in the HUVECs, which triggers
the inhibition of the c-kit and impairs the HUVEC
Figure 3 Correlation of miR-155, miR-146a expressions and urinary protein excretion, serum creatinine of the DN patients. Urinary
protein was measured by a competitive ELISA and the serum creatinine level was detected by a QuantiChrom Creatinine Assay. The miR-155 and
miR-146a expression levels were confirmed by a real-time PCR. A linear correlation analysis was performed between the miR-155 and urinary
protein (A); miR-155 and serum creatinine (B); miR-146a and urinary protein (C); and miR-146a and serum creatinine (D). The linear correlation
analysis showed the expression of miR-155 was closely correlated with the serum creatinine level (R = 0.95, P = 0.004).
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DN progression, and miR-215 has been shown to function
as a key endogenous gene-silencing factor that mediates
the TGF-β1-induced MC activation and fibronectin ex-
pression via the CTNNBIP1/β-catenin pathway [27].
The identification of new and key regulatory miRNAs
in DN would be of great importance, and the present
study found that among the 32 miRNAs up-regulated in
the DN patients, miR-155 and miR-146a were significantlyTable 3 Serum creatinine and urinary protein excretion in typ
Parameters T1DM-week 0
Serum creatinine (μmol/L) 33.9 ± 7.1
urinary protein excretion (mg/24 h) 101.6 ± 9.8
Note: avs week 0 (p < 0.05); bvs week 4 (p < 0.05).increased and primarily distributed in the GECs, mesan-
gial areas and tubular sections. Furthermore, miR-155 and
miR-146a were gradually up-regulated during the develop-
ment and progression of type 1 and type 2 DN, indicating
that they could be activated in a rat DN model. We de-
tected miR-155 expression was closely correlated with
serum creatinine levels, Creatinine clearance was used to
calculate estimated glomerular filtration rate (eGFR) for de-
tection of kidney dysfunction. When in patients particularlye 1 diabetes rat models
T1DM-week 4 T1DM-week 8
53.6 ± 11.2a 82.4 ± 20.0 ab
227.8 ± 72.4a 296.9 ± 79.6 ab
Figure 4 Expression of miR-155 and miR146a in the
STZ-induced rat kidney with type 1 diabetic nephropathy.
Quantitative real-time PCR was used to detect the expressions of
miR-155 (A) and miR-146a (B) in the kidney of a STZ-induced Type 1
diabetic nephropathy model. Compared with the normal controls,
the expressions of miR-155 and miR-146a were gradually increased
from the time point of week 1 to week 8. *p < 0.05.
Figure 5 Expression of miR-155 and miR146a in high-fat and
high-sugar diet combined with STZ-induced rat kidney with
type 2 diabetic nephropathy. Quantitative real-time PCR was used
to detect the expressions of miR-155 (A) and miR-146a (B) in the
kidney of the Type 2 diabetic nephropathy model. Compared with
the control group, the expressions of miR-155 and miR-146a were in-
creased at the time points of week 8 and week 16. *p < 0.05.
Table 4 Serum creatinine and urinary protein excretion in







Serum creatinine (μmol/L) 28.6 ± 6.2 60.4 ± 6.9a 98.5 ± 24.7 ab
Urinary protein
excretion (mg/24 h)
130.5 ± 8.4 283.2 ± 69.5a 378.2 ± 85.9 ab
Note: avs week 0 (p < 0.05); bvs week 8 (p < 0.05).
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overestimates the GFR [28], therefore miR-155 may be a
good marker for prediction the GFR of the DN. miR-146a
expression was not correlated with serum creatinine levels
or urinary protein excretion, this lack of correlation could
reflect the limited sample size and consequent low statis-
tical power, therefore, it needs our further investigation
with more samples.
In a murine model of chronic kidney disease (CKD),
the expression of miR-146a was elevated in B6.MRLc1
CKD mice and shown to increase with the development
of CKD [29]. A histopathological analysis of glomerular
and interstitial lesions revealed that the mRNA expres-
sion of inflammatory mediators was significantly higher
in B6.MRLc1 than in C57BL/6 mice, which may have
been induced by increased miR-146a [29], as observed in
our in situ hybridization results. Our experiments con-
firmed that high glucose can increase the expression of
miR-155 and miR-146a in a time-dependent manner.
The high glucose-induced up-regulation of TNF-α and
TGF-β1 was augmented by the overexpression of miR-155 and miR-146a, thereby increasing renal inflamma-
tion and fibrosis and enhancing diabetic GEC injury,
which is mediated through the activation of the NF-κB
signaling pathway.
Researchers found that miR-155 directly targets SMAD5
[30] and SMAD2 [31]. In DN, bone morphogenetic pro-
tein 7 (BMP-7) is down-regulated [32], and previous
in vitro studies have shown that BMP-7-induced Smad5
reduces Smad2/3 signaling downstream of TGF-β [33,34].
This leads to the down-regulation of TGF-β-dependent
profibrogenic events in cultured cells, thus increasing the
expression levels of fibrosis-associated extracellular matrix
proteins in glomeruli and the cortical interstitium [33].
Researchers found that TGF-β can lead to the phosphoryl-
ation of Smad2/Smad3, which associates with Smad4 as a
Figure 6 Impact of miR-155 and miR-146a on HRGECs. A, B. The expression of miR-155 and miR-146 under high glucose conditions of
different times compared with the control and mannitol group; C, D. Quantification of miR-155 and miR-146a mRNA expression levels with
different treating methods on HRGECs by a real-time PCR; E, F. Western blot was used to assess the protein levels of TNF-α and TGF-β with the
same treating methods in C and D, glucose group is compared with mannitol group; the high glucose +miR155 inhibitor and high glucose +
miR155 mimics are compared to high glucose + scrambled miRNA. High glucose + PDTC is compared with high glucose +miR-155 + PDTC group;
G, H. Extracted nuclear proteins were incubated with a biotin-labeled NF-κB probe to detect the DNA-binding activity of NF-κB. Lane 1, normal
control group; lane 2, high glucose (25 mmol/L); lane 3, high glucose +miR-155/146a mimics (50 nmol/L); lane 4, high glucose + miR-155/146a
inhibitor (100 nmol/L); lane 5, high glucose + PDTC (100 umol/L); lane 6, high glucose +miR-155/146a (50 nmol/L) + PDTC (100 μmol/L). *p < 0.05.
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http://www.biomedcentral.com/1471-2369/15/142heteromeric complex and translocates to the nucleus. This
complex binds directly to Smad-binding elements and as-
sociates with a plethora of transcription factors, thusleading to the transcriptional induction or repression of a
diverse array of genes. William Kong el al. found Smad4
can directly bind to the promoter of miR-155 and can be
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fore, miR-155 and TGF-β1 may form a positive regulation
loop mediated by the SMAD signaling pathway.
In the monocytic leukemia cell line THP-1, Konstantin
et al. [8] observed the induction of miR-146a in response
to TNF-α. This was found to be mediated by NF-κB, as
mutations in the NF-κB binding site of the miR-146a pro-
moter impaired the TNF-α activation effect. Moreover,
data have shown that miR-155 can be up-regulated by
TNF-α through NF-κB [36]. Together with our findings
from the present study, these results lead us to speculate
that miR-155 and miR-146a form a regulatory loop in the
TNF-α/NF-κB pathway during DN development.
Conclusions
In conclusion, the present study provides direct biological
evidence for the pathogenic importance of miR-155 and
miR-146a in DN. Our results demonstrated that miR-155
and miR-146a were up-regulated in the DN patient and ex-
perimental animal models and served as a mediator of the
glucose-induced TNF-α/TGF-β1-NF-κB pathway. Taken
together, these findings suggest that miR-155 and miR-146a
are not only biomarkers but also mediators in the develop-
ment of DN. Determination of the detailed miR-155 and
miR-146a mechanisms that cause renal damage in the set-
ting of diabetes could elucidate the pathogenesis of DN and
enable improved treatment strategies to be developed.
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